TGCT
MCID: PGM001
MIFTS: 55

Pigmented Villonodular Synovitis (TGCT)

Categories: Bone diseases, Muscle diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Pigmented Villonodular Synovitis

MalaCards integrated aliases for Pigmented Villonodular Synovitis:

Name: Pigmented Villonodular Synovitis 12 73 20 58 15 17 70
Tenosynovial Giant Cell Tumor 20 58
Diffuse-Type Giant Cell Tumor 20 58
Diffuse-Type Gct 20 58
Tsgct 20 58
Tgct 20 58
Localized Pigmented Villonodular Synovitis 20
Diffuse Giant Cell Tumor of Tenosynovium 12
Diffuse Pigmented Villonodular Synovitis 20
Fibrous Histiocytoma of Tendon Sheath 70
Synovitis, Pigmented Villonodular 44
Synovitis Pigmented Villonodular 54
Tenosynovial Giant Cell Tumors 20
Testicular Germ Cell Tumor 70
Villous Tenosynovitis 12

Characteristics:

Orphanet epidemiological data:

58
pigmented villonodular synovitis
Inheritance: Not applicable;

Classifications:

Orphanet: 58  
Rare systemic and rhumatological diseases


External Ids:

Disease Ontology 12 DOID:2702
MeSH 44 D013586
NCIt 50 C3401
SNOMED-CT 67 202903009
ICD10 32 M12.2
MESH via Orphanet 45 D013586
ICD10 via Orphanet 33 M12.2
UMLS via Orphanet 71 C0039106
Orphanet 58 ORPHA66627
UMLS 70 C0039106 C1318543 C1336708

Summaries for Pigmented Villonodular Synovitis

GARD : 20 Pigmented villonodular synovitis (PVNS) is a disease in which the tissue lining the joints and tendons in the body (synovium) grows abnormally. It is characterized by a noncancerous mass or tumor. There are two types of PVNS: the local or nodular form (where the tumor involves the tendons that support the joint, or in one area of the joint) and the diffuse form (where the entire lining of the joint is involved). Symptoms might include: pain, limitation of movement, and locking of the joint. In some cases, the normal joint structure can be destroyed. The knee is most commonly affected by this condition, though it can occur in other joints such as the hip, shoulder, elbow, ankle, wrist, and rarely the jaw. The average age of diagnosis for this condition is 35 years. The cause of PVNS is unknown. Treatment involves surgery to remove the tumor and damaged portions of the synovium.

MalaCards based summary : Pigmented Villonodular Synovitis, also known as tenosynovial giant cell tumor, is related to synovitis and villonodular synovitis, and has symptoms including pain An important gene associated with Pigmented Villonodular Synovitis is CSF1 (Colony Stimulating Factor 1), and among its related pathways/superpathways are Innate Immune System and PAK Pathway. The drugs Carboplatin and Sargramostim have been mentioned in the context of this disorder. Affiliated tissues include bone, breast and skin, and related phenotypes are arthralgia and joint stiffness

Wikipedia : 73 Tenosynovial giant cell tumor (TGCT) is a group of rare, typically non-malignant tumors of the joints.... more...

Related Diseases for Pigmented Villonodular Synovitis

Diseases related to Pigmented Villonodular Synovitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 317)
# Related Disease Score Top Affiliating Genes
1 synovitis 32.4 TNFSF11 MMP9 CD68 ACP5
2 villonodular synovitis 32.0 PTPRC PTPN11 MMP9 CSF1 CD68 ACP5
3 tenosynovial giant cell tumor 31.0 SERPINA3 CSF1R CSF1 CD68
4 pleomorphic lipoma 30.7 SERPINA3 CD68
5 arthritis 30.3 TNFSF11 MMP9 CSF1R CSF1 ACP5
6 chondroblastoma 30.2 TNFSF11 SERPINA3 PTHLH
7 rheumatoid arthritis 30.2 TNFSF11 MMP9 CSF1R CSF1 ACP5
8 giant cell reparative granuloma 30.1 TNFSF11 SERPINA3 CD68 CALCR
9 pectus excavatum 30.1 TP53 PTPN11
10 benign giant cell tumor 30.1 TNFSF11 SERPINA3 PTPRC MMP9 CSF1R CSF1
11 multicentric reticulohistiocytosis 30.1 TNFSF11 SERPINA3 CSF1 CD68
12 paget's disease of bone 30.0 TNFSF11 PTHLH CSF1 ACP5
13 nodular tenosynovitis 29.8 SERPINA3 PTPRC CSF1 CD68 ACP5
14 bone giant cell tumor 29.7 TNFSF11 SERPINA3 CSF1 CD68 CALCR ACP5
15 malignant fibrous histiocytoma 29.6 TP53 SERPINA3 PTPRC CD68
16 bone sarcoma 29.5 TP53 SERPINA3 CSF1 CASP3
17 bone resorption disease 29.4 TNFSF11 SERPINA3 PTHLH CSF1 CALCR ACP5
18 noonan syndrome 1 11.8
19 plica syndrome 11.6
20 testicular germ cell tumor 11.6
21 testicular cancer 11.1
22 tenosynovitis 10.7
23 hemarthrosis 10.7
24 frozen shoulder 10.7
25 bursitis 10.7
26 synovial chondromatosis 10.7
27 popliteal cyst 10.6
28 soft tissue sarcoma 10.6
29 arthropathy 10.5
30 sarcoma, synovial 10.5
31 osteonecrosis 10.5
32 juvenile rheumatoid arthritis 10.5
33 hemangioma 10.4
34 malignant giant cell tumor 10.4
35 synovial angioma 10.4
36 chromosomal triplication 10.4
37 triiodothyronine receptor auxiliary protein 10.4
38 sarcoma 10.4
39 spindle cell sarcoma 10.4
40 septic arthritis 10.4
41 osteoarthritis 10.4
42 neuropathy 10.4
43 hemophilia 10.4
44 pseudo-turner syndrome 10.4
45 avascular necrosis 10.4
46 rare tumor 10.4
47 chondrosarcoma 10.3
48 rare soft tissue tumor 10.3
49 thyroid carcinoma 10.3
50 hypertelorism, microtia, facial clefting syndrome 10.3 TNFSF11 PTPN11

Graphical network of the top 20 diseases related to Pigmented Villonodular Synovitis:



Diseases related to Pigmented Villonodular Synovitis

Symptoms & Phenotypes for Pigmented Villonodular Synovitis

Human phenotypes related to Pigmented Villonodular Synovitis:

58 31 (show all 23)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 arthralgia 58 31 hallmark (90%) Very frequent (99-80%) HP:0002829
2 joint stiffness 58 31 frequent (33%) Frequent (79-30%) HP:0001387
3 joint swelling 58 31 frequent (33%) Frequent (79-30%) HP:0001386
4 osteolysis 58 31 frequent (33%) Frequent (79-30%) HP:0002797
5 abnormality of the knee 58 31 frequent (33%) Frequent (79-30%) HP:0002815
6 lymphedema 58 31 occasional (7.5%) Occasional (29-5%) HP:0001004
7 conductive hearing impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0000405
8 abnormality of the ankles 58 31 occasional (7.5%) Occasional (29-5%) HP:0003028
9 abnormality of the elbow 58 31 occasional (7.5%) Occasional (29-5%) HP:0009811
10 multiple lentigines 58 31 occasional (7.5%) Occasional (29-5%) HP:0001003
11 abnormality of the wrist 58 31 occasional (7.5%) Occasional (29-5%) HP:0003019
12 abnormal temporal bone morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0009911
13 abnormality of the tympanic membrane 58 31 occasional (7.5%) Occasional (29-5%) HP:0040090
14 abnormality of the auditory canal 58 31 occasional (7.5%) Occasional (29-5%) HP:0000372
15 abnormality of the hip joint 58 31 occasional (7.5%) Occasional (29-5%) HP:0001384
16 groin pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0031520
17 abnormal shoulder morphology 31 occasional (7.5%) HP:0003043
18 chondrocalcinosis 58 31 very rare (1%) Very rare (<4-1%) HP:0000934
19 synovial hypertrophy 58 31 very rare (1%) Very rare (<4-1%) HP:0005186
20 polyarticular arthropathy 58 31 very rare (1%) Very rare (<4-1%) HP:0005195
21 localized osteoporosis 58 31 very rare (1%) Very rare (<4-1%) HP:0040161
22 limitation of joint mobility 58 Frequent (79-30%)
23 abnormality of the shoulder 58 Occasional (29-5%)

UMLS symptoms related to Pigmented Villonodular Synovitis:


pain

MGI Mouse Phenotypes related to Pigmented Villonodular Synovitis:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.28 CALCR CASP3 CD68 CSF1 CSF1R MMP9
2 behavior/neurological MP:0005386 10.27 CALCR CASP3 CSF1 CSF1R MMP9 PTHLH
3 homeostasis/metabolism MP:0005376 10.26 CALCR CASP3 CSF1 CSF1R MMP9 PTHLH
4 immune system MP:0005387 10.25 CALCR CASP3 CD68 CSF1 CSF1R MMP9
5 integument MP:0010771 10.19 CASP3 CSF1 CSF1R MMP9 PTHLH PTPN11
6 endocrine/exocrine gland MP:0005379 10.15 CASP3 CSF1 CSF1R PTHLH PTPN11 PTPRC
7 mortality/aging MP:0010768 10.13 CALCR CASP3 CSF1 CSF1R MMP9 PTHLH
8 craniofacial MP:0005382 10.11 CASP3 CSF1 CSF1R PTHLH PTPN11 TNFSF11
9 limbs/digits/tail MP:0005371 10.08 CALCR CSF1 CSF1R MMP9 PTHLH PTPN11
10 digestive/alimentary MP:0005381 10.03 CASP3 MMP9 PTHLH PTPN11 PTPRC TP53
11 liver/biliary system MP:0005370 9.93 CALCR CSF1 PTHLH PTPN11 PTPRC TP53
12 no phenotypic analysis MP:0003012 9.92 CASP3 CD68 CSF1 CSF1R PTPN11 PTPRC
13 muscle MP:0005369 9.88 CASP3 CSF1 MMP9 PTPN11 TNFSF11 TP53
14 neoplasm MP:0002006 9.85 MMP9 PTHLH PTPN11 PTPRC TNFSF11 TP53
15 normal MP:0002873 9.8 CALCR CSF1R PTHLH PTPN11 PTPRC TNFSF11
16 reproductive system MP:0005389 9.76 CASP3 CSF1 CSF1R MMP9 PTHLH PTPN11
17 respiratory system MP:0005388 9.56 CASP3 CSF1 MMP9 PTHLH PTPN11 PTPRC
18 skeleton MP:0005390 9.36 CALCR CASP3 CD68 CSF1 CSF1R MMP9

Drugs & Therapeutics for Pigmented Villonodular Synovitis

Drugs for Pigmented Villonodular Synovitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 64)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
2
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
3
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
4
Ifosfamide Approved Phase 2 3778-73-2 3690
5
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
6
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
7
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
8
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
9
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
10
Dactinomycin Approved, Investigational Phase 2 50-76-0 2019 457193
11
Etoposide Approved Phase 2 33419-42-0 36462
12
Lenograstim Approved, Investigational Phase 2 135968-09-1
13
leucovorin Approved Phase 2 58-05-9 6006
14
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
15
Olaparib Approved Phase 2 763113-22-0 23725625
16
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
17
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
18
Durvalumab Approved, Investigational Phase 2 1428935-60-7
19
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
20
Ethanol Approved Phase 2 64-17-5 702
21
Disulfiram Approved Phase 2 97-77-8 3117
22
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
23
Tremelimumab Investigational Phase 2 745013-59-6
24 Antimetabolites Phase 2
25 Grapefruit Seed Extract Phase 2
26
Isophosphamide mustard Phase 2 100427
27 Tubulin Modulators Phase 2
28 Albumin-Bound Paclitaxel Phase 2
29 Antimitotic Agents Phase 2
30 Alkylating Agents Phase 2
31 Anti-Infective Agents Phase 2
32
Liposomal doxorubicin Phase 2 31703
33 Antirheumatic Agents Phase 2
34 Micronutrients Phase 2
35 Antidotes Phase 2
36 Trace Elements Phase 2
37 Vitamin B9 Phase 2
38 Nutrients Phase 2
39 Folic Acid Antagonists Phase 2
40 Vitamin B Complex Phase 2
41 Antibiotics, Antitubercular Phase 2
42 Folate Phase 2
43 Anti-Bacterial Agents Phase 2
44 Etoposide phosphate Phase 2
45 Protective Agents Phase 2
46 Vitamins Phase 2
47 Calcium, Dietary Phase 2
48 Dermatologic Agents Phase 2
49 Antineoplastic Agents, Immunological Phase 2
50 Poly(ADP-ribose) Polymerase Inhibitors Phase 2

Interventional clinical trials:

(show all 34)
# Name Status NCT ID Phase Drugs
1 A Phase 4, Multicenter Study to Evaluate Discontinuation and Re-Treatment in Subjects With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib Recruiting NCT04526704 Phase 4 Pexidartinib
2 Trial of Imaging and Schedule in Seminoma Testis Unknown status NCT00589537 Phase 3
3 Carboplatin in the Adjuvant Treatment of Stage I Seminoma: A Radomized Comparison of Single Agent Carboplatin With Radiotherapy in the Adjuvant Treatment of Stage I Seminoma of the Testis, Following Orchidectomy Completed NCT00003014 Phase 3 carboplatin
4 Multicenter, Single Arm Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With Tenosynovial Giant Cell Tumor Recruiting NCT04488822 Phase 3 Pexidartinib
5 A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects With Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath Active, not recruiting NCT02371369 Phase 3 Pexidartinib;Placebo
6 A Phase 1/2 Study of Cabiralizumab, an Anti-CSF1 Receptor Antibody, in Patients With Pigmented Villonodular Synovitis (PVNS)/ Diffuse Type Tenosynovial Giant Cell Tumor (Dt-TGCT) Completed NCT02471716 Phase 1, Phase 2
7 Phase II Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT) Completed NCT01261429 Phase 2 Tasigna
8 A Phase II Randomized, Double -Blind, Placebo Controlled Study to Assess Safety, Tolerability and Effect on Tumor Size of MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) Completed NCT01643850 Phase 2 MCS110;Placebo
9 A Study of Paclitaxel, Cisplatin and Ifosfamide as Induction Therapy in the Treatment of Patients Relapsing After BEP Chemotherapy for Metastatic Germ Cell Tumors Completed NCT00004077 Phase 2 cisplatin;ifosfamide;paclitaxel
10 PROTOCOL FOR THE TREATMENT OF MALIGNANT NON-TESTICULAR GERM CELL TUMORS Completed NCT00002489 Phase 2 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;leucovorin calcium;methotrexate;vincristine sulfate
11 A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor Recruiting NCT03069469 Phase 1, Phase 2 DCC-3014
12 A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors Recruiting NCT02029001 Phase 2 Nilotinib (400 mg BID);Everolimus (10 mg QD);Sorafenib (400 mg BID);Lapatinib (1500 mg QD);Pazopanib (800 mg QD);Olaparib (300 mg BID)
13 Phase II Single-arm Trial to Evaluate Progression Free Survival With Primary Retroperitoneal Lymph-node Dissection (pRPLND) Only in Patients With Seminomatous Testicular Germ Cell Tumors With Clinical Stage IIA/B (PRIMETEST) Recruiting NCT02797626 Phase 2
14 Phase II Study of Disulfiram and Cisplatin in Refractory TGCTs. Recruiting NCT03950830 Phase 2 Disulfiram
15 A Multi-Center Single Agent Phase II Study of the Efficacy of Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor Active, not recruiting NCT01207492 Phase 2 nilotinib
16 An Adaptive, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee Not yet recruiting NCT04731675 Phase 2
17 A Phase 2, Multicenter, Two-Part, Open-Label Study of Pexidartinib in Adult Subjects With Tenosynovial Giant Cell Tumor in Japan Not yet recruiting NCT04703322 Phase 2 Pexidartinib
18 Phase I Study of the Hypomethylating Drug SGI-110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors Completed NCT02429466 Phase 1 Guadecitabine (SGI-110)
19 Phase I Study to Determine the Safety of MEN-10755 (BMS-195615) in Patients With a Solid Tumor on a Short I.V. Infusion Given Once Every Week for 3 Consecutive Weeks, Followed by One Week's Rest Completed NCT00003982 Phase 1 sabarubicin
20 A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX73086 as a Single Agent in Subjects With Advanced Solid Tumors and in Subjects With Locally Advanced or Refractory Tenosynovial Giant Cell Tumor (TGCT) Terminated NCT02673736 Phase 1 PLX73086
21 Evaluation of the Effectiveness of Surgical Treatment of Villo-nodular Synovitis of the Hip in Children in a Retrospective Case Series Unknown status NCT03507933
22 Assessment of the Utility of CT Follow Up in the Long Term Follow Up of Patients With Metastatic Non Seminomatous Germ Cell Tumour (NSGCT) Unknown status NCT00553371
23 A Study of the Natural History of Cisplatin-Induced Peripheral Neuropathy in Patients With Germ Cell Tumor Completed NCT02677727
24 A Multicentric Case-control Study to Assess the Association Between Environmental, Domestic and Occupational Exposures During Antenatal and Early Postnatal Periods and the Risk to Develop a Testicular Germ Cell Tumor During Adulthood Completed NCT02109926
25 Correlation of Histopathology, Immunohistochemistry and Quantitative Radiology With Outcome in Early Stage Nonseminomatous Germ Cell Tumor Completed NCT00003800
26 A Study Of 18 FDG PET In The Prediction Of Relapse In Patients With A Clinical Stage I Non-Seminomatous Germ Cell Tumor Completed NCT00045045
27 A Study of CT Scan Frequency in Patients With Stage I Testicular Teratoma Completed NCT00003420
28 Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Studies of Familial Testicular Germ Cell Tumors Completed NCT00342537
29 A Case-Control Study of Testicular Germ Cell Tumors Among U.S. Military Servicemen Completed NCT00341588
30 Exploratory Study of Molecular Characterization in Patients With Metastatic Germ Cell Tumours Refractory/Resistant to Platinum Treatment Recruiting NCT03980587
31 Toxicity Attributed to Genetic Polymorphisms in Testicular Germ Cell Tumor Survivors Recruiting NCT02303015
32 Financial Toxicity and Quality of Life in Patients With Testicular Germ Cell Tumors Recruiting NCT04531709
33 A Disease Registry for Patients With Tenosynovial Giant Cell Tumors (TGCT), Also Known as Pigmented Villonodular Synovitis (PVNS) and Giant Cell Tumor of the Tendon Sheath (GCT-TS) Active, not recruiting NCT02948088
34 Sentinel Lymph Node Procedure in Testicular Germ Cell Tumour Not yet recruiting NCT03448822

Search NIH Clinical Center for Pigmented Villonodular Synovitis

Cochrane evidence based reviews: synovitis, pigmented villonodular

Genetic Tests for Pigmented Villonodular Synovitis

Anatomical Context for Pigmented Villonodular Synovitis

MalaCards organs/tissues related to Pigmented Villonodular Synovitis:

40
Bone, Breast, Skin, Lymph Node, Testis, Myeloid, Tongue

Publications for Pigmented Villonodular Synovitis

Articles related to Pigmented Villonodular Synovitis:

(show top 50) (show all 1291)
# Title Authors PMID Year
1
Tenosynovial Giant Cell Tumor: Incidence, Prevalence, Patient Characteristics, and Recurrence. A Registry-based Cohort Study in Denmark. 20
28765257 2017
2
Cytogenetic analysis of a primary bone angiosarcoma. 61 54
19737647 2009
3
99mTc-MDP 3-Phase Bone Imaging in 3 Cases of Pigmented Villonodular Synovitis. 61
33630800 2021
4
cIAP2 expression and clinical significance in pigmented villonodular synovitis. 61
33599891 2021
5
Modified Stoppa Approach: Beyond Acetabular Fractures: A Report of 2 Cases. 61
33798123 2021
6
Spinal pigmented villonodular synovitis and tenosynovial giant cell tumor: A report of two cases and a comprehensive systematic review. 61
33596487 2021
7
Subacromial pigmented villonodular synovitis: case report and review. 61
33732422 2021
8
Pigmented Villonodular Synovitis of the Hip in Patients Undergoing Total Hip Arthroplasty: A Retrospective Case-Controlled Analysis. 61
32978024 2021
9
Long-term functional outcomes of diffuse pigmented villonodular synovitis of knee: The role of adjuvant radiotherapy. 61
33761628 2021
10
The New Bern Chondrolabral Classification Is Reliable and Reproducible. 61
33787519 2021
11
MRI evaluation of solid soft tissue masses of the fingers with pathology correlation. 61
33341071 2021
12
Pigmented Villonodular Synovitis of the Flexor Hallucis Longus Tendon Treated by Means of Tendoscopy and Endoscopic Synovectomy. 61
33750654 2021
13
Short-Term Outcomes of Synovectomy and Total Knee Replacement in Patients with Diffuse-Type Pigmented Villonodular Synovitis. 61
31434148 2021
14
Subtalar joint pigmented villonodular synovitis misdiagnosed at the first visit: A case report. 61
33644205 2021
15
Systematic review: total knee arthroplasty (TKA) in patients with pigmented villonodular synovitis (PVNS). 61
33632334 2021
16
Tenosynovial Giant Cell Tumor of the Retropharynx: A Case Report With Literature Review. 61
33048582 2021
17
Atypical and bilateral pigmented villonodular synovitis of wrist in an adolescent patient: case report and literature review. 61
33786156 2021
18
An abrupt-onset shoulder joint subluxation and pseudoparalysis caused by intraarticular pigmented villonodular synovitis: A case report. 61
33463448 2021
19
Open synovectomy treatment for intra- and extraarticular localized pigmented villonodular synovitis of the knee: a case report. 61
33413272 2021
20
Case Report: Extra-Articular Diffuse Tenosynovial Giant Cell Tumor of the Temporomandibular Joint. 61
33718242 2021
21
Pigmented Villonodular Synovitis of the Knee Joint in a 10-Year-Old Patient Treated With an All-Arthroscopic Synovectomy: A Case Report. 61
33425510 2020
22
Villonodular synovitis of the lumbar spine: Case report of a rare pathology. 61
33363737 2020
23
[Rheumatoid arthritis combined with pigmented villonodular synovitis: A case report and literature review]. 61
33331327 2020
24
Fibroma of tendon sheath of the hand in a 3-year-old boy: a case report. 61
33172434 2020
25
Synovial Non-langerhans Cell Histiocytosis of the Shoulder: A Case Report and Review of the Literature. 61
33708700 2020
26
Radioisotope Synoviorthesis in the Control of Refractory Synovitis in Castilla-La Mancha. A 10-year Experience. 61
30691947 2020
27
Management of Tenosynovial Giant Cell Tumor: A Neoplastic and Inflammatory Disease. 61
33156160 2020
28
Prospects of Treating Tenosynovial Giant Cell Tumor through Pexidar-tinib: A Review. 61
33143617 2020
29
Pigmented villonodular synovitis does not influence the outcomes following cruciate-retaining total knee arthroplasty: a case-control study with minimum 5-year follow-up. 61
32894157 2020
30
ENLIVEN study: Pexidartinib for tenosynovial giant cell tumor (TGCT). 61
32755241 2020
31
Optimal Treatment for Tenosynovial Giant Cell Tumor of the Hand. 61
32350187 2020
32
Pigmented Villonodular Synovitis Mimicking an Acute Septic Hip in an Eight-Year-Old Male. 61
32968561 2020
33
Pigmented villonodular synovitis of the hip joint: Three cases demonstrating characteristic MRI features. 61
32617126 2020
34
Acupuncture improves postoperative symptoms of pigmented villonodular synovitis: A protocol for systematic review and meta analysis. 61
32872065 2020
35
Concomitant Spondyloarthritis and Tenosynovial Giant Cell Tumor in Pigmented Villonodular Synovitis Challenging Cases. 61
30601200 2020
36
Pigmented Villonodular Synovitis: Novel Role of Dual-Energy CT. 61
30614893 2020
37
Dark as night: Spelunking for spinal solitary fibrous tumors/hemangiopericytomas in the differential of T2 hypointensity. 61
32507710 2020
38
Tenosynovial giant cell tumor in the foot and ankle. 61
31526689 2020
39
Clinical and immunohistochemical analysis of diffuse tenosynovial giant cell tumour of the temporomandibular joint. 61
32014315 2020
40
Concurrence of Pigmented Villonodular Synovitis with Calcium Pyrophosphate Deposition in a Postacute Stroke Patient. 61
33282666 2020
41
Ozone therapy for the treatment of recurrent pigmented villonodular synovitis of the knee. 61
33004715 2020
42
Management of Pigmented Villonodular Synovitis (PVNS): an Orthopedic Surgeon's Perspective. 61
32494892 2020
43
Mid-Term Results of Arthroscopic Synovectomy for Pigmented Villonodular Synovitis of the Hip. 61
32061973 2020
44
Identification of Patient Needs and Preferences in Pigmented Villonodular Synovitis (PVNS) Using a Qualitative Online Bulletin Board Study. 61
32394210 2020
45
Tenosynovial Giant Cell Tumor in the Hand: Experience with 173 Cases. 61
32312203 2020
46
Tenosynovial Giant Cell Tumor, Localized Type With Extensive Chondroid Metaplasia: A Case Report With Immunohistochemical and Molecular Genetic Analysis. 61
31771368 2020
47
Efficacy of image-guided synovial biopsy. 61
31912178 2020
48
Spontaneous swelling of the ankle in a child : a difficult diagnosis. 61
33418627 2020
49
A Rare Case of Hip Pain Secondary to Pigmented Villonodular Synovitis. 61
32426678 2020
50
Recurrence of pigmented villonodular synovitis of the knee: A case report with review of literature on the risk factors causing recurrence. 61
32312009 2020

Variations for Pigmented Villonodular Synovitis

Expression for Pigmented Villonodular Synovitis

Search GEO for disease gene expression data for Pigmented Villonodular Synovitis.

Pathways for Pigmented Villonodular Synovitis

Pathways related to Pigmented Villonodular Synovitis according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.25 TP53 TNFSF11 SERPINA3 PTPRC PTPN11 MMP9
2
Show member pathways
13.02 TNFSF11 PTPRC PTPN11 CSF1R CSF1 CASP3
3
Show member pathways
12.84 TP53 TNFSF11 PTPRC MMP9 CASP3
4 12.54 TP53 CSF1R CSF1 CASP3
5
Show member pathways
12.28 TP53 TNFSF11 PTPN11 MMP9 CSF1R CSF1
6
Show member pathways
12.13 TNFSF11 CSF1R CSF1 CALCR ACP5
7 12.02 TP53 PTPN11 MMP9 CASP3
8 11.79 TP53 MMP9 CASP3
9 11.76 PTPRC CSF1 CD68
10 11.74 MMP9 CSF1 CASP3
11 11.64 TNFSF11 CSF1 ACP5
12 11.51 PTPRC PTPN11 MMP9
13 11.48 PTPRC CSF1R CSF1
14 11.25 TP53 PTPN11 CASP3
15 11.18 TNFSF11 CSF1R CSF1
16 11.1 PTPN11 CSF1R CSF1
17 10.76 TNFSF11 ACP5
18 10.75 CSF1 CD68

GO Terms for Pigmented Villonodular Synovitis

Cellular components related to Pigmented Villonodular Synovitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CSF1-CSF1R complex GO:1990682 8.62 CSF1R CSF1

Biological processes related to Pigmented Villonodular Synovitis according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.71 PTPRC PTPN11 CSF1R CALCR
2 ossification GO:0001503 9.69 TNFSF11 MMP9 ACP5
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.67 TP53 PTPRC PTPN11
4 hematopoietic progenitor cell differentiation GO:0002244 9.61 TP53 PTPRC CSF1R
5 bone resorption GO:0045453 9.59 TNFSF11 ACP5
6 positive regulation of osteoclast differentiation GO:0045672 9.58 TNFSF11 CSF1
7 negative regulation of chondrocyte differentiation GO:0032331 9.58 PTPN11 PTHLH
8 neurotrophin TRK receptor signaling pathway GO:0048011 9.57 PTPN11 CASP3
9 response to X-ray GO:0010165 9.56 TP53 CASP3
10 platelet formation GO:0030220 9.55 PTPN11 CASP3
11 positive regulation of macrophage chemotaxis GO:0010759 9.54 CSF1R CSF1
12 response to ischemia GO:0002931 9.54 TP53 CSF1R CSF1
13 response to amyloid-beta GO:1904645 9.52 MMP9 CALCR
14 bone marrow development GO:0048539 9.48 TP53 PTPRC
15 microglial cell proliferation GO:0061518 9.46 CSF1R CSF1
16 macrophage differentiation GO:0030225 9.33 MMP9 CSF1R CSF1
17 macrophage colony-stimulating factor signaling pathway GO:0038145 9.32 CSF1R CSF1
18 osteoclast proliferation GO:0002158 9.26 TNFSF11 CSF1
19 osteoclast differentiation GO:0030316 9.26 TNFSF11 CSF1R CSF1 CALCR
20 cytokine-mediated signaling pathway GO:0019221 9.17 TP53 TNFSF11 PTPN11 MMP9 CSF1R CSF1

Molecular functions related to Pigmented Villonodular Synovitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide hormone receptor binding GO:0051428 8.62 PTPN11 PTHLH

Sources for Pigmented Villonodular Synovitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....